The treatment of cancer has made great progress. However, drug resistance remains problematic. Multiple physiologic processes of tumor development can be dominated by central and sympathetic nervous systems. The interactions between the nervous system, immune system, and tumor occur consistently and dynamically. Recent evidence suggests that nerves and neural signals are intimately involved in the development of resistance to cancer therapies. In this review, we will provide an overview of the recent progress in this rapidly growing area and discuss the potential new strategies for targeting the neural signaling pathway to improve the effectiveness of chemotherapies, targeted therapies, and immunotherapies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bbcan.2018.10.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Discovery of natural products as influenza neuraminidase inhibitors: in silico screening, in vitro validation, and molecular dynamic simulation studies.
Mol Divers
January 2025
Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, 350001, Fujian, China.
Influenza is a highly contagious respiratory illness that imposes a significant global burden. Antiviral neuraminidase inhibitors (NAIs) such as oseltamivir (OC) have been proven essential, but the emergence of resistant viral strains necessitates the development of novel therapies. This study explored the potential of natural products as alternative NAIs.
View Article and Find Full Text PDFBeyond checkpoint inhibitors: the three generations of immunotherapy.
Clin Exp Med
January 2025
LSU-LCMC Cancer Center, LSU School of Medicine, 1700 Tulane Avenue, Room 510, New Orleans, LA, 70112, USA.
Anti-tumor immunotherapy was rediscovered and rejuvenated in the last two decades with the discovery of CTLA-4, PD-1 and PD-L1 and the roles in inhibiting immune function and tumor evasion of anti-tumor immune response. Following the approval of the first checkpoint inhibitor ipilimumab against CTLA-4 in melanoma in 2011, there has been a rapid development of tumor immunotherapy. Furthermore, additional positive and negative molecules among the T-cell regulatory systems have been identified that that function to fine tune the stimulatory or inhibitory immune cells and modulate their functions (checkpoint modulators).
View Article and Find Full Text PDFTargets Selection for Precision Therapy of Relapsed/Refractory Multiple Myeloma: the Latest Advancements.
Curr Treat Options Oncol
January 2025
Tianjin Medical University General Hospital, 154 Anshan Road, Tianjin, 300052, Heping District, China.
According to the guidelines, the primary treatment for multiple myeloma is still based on drugs such as carfilzomib, lenalidomide, or daratumumab. However, patients with relapsed/refractory multiple myeloma (RRMM) may be insensitive or develop resistance to the above therapeutic medications. Thus, formulating standardized and rational treatment regimens for such patients remains an area for consideration.
View Article and Find Full Text PDFEpstein-Barr virus-infected nasopharyngeal carcinoma therapeutics: oncoprotein targets and clinical implications.
Med Oncol
January 2025
School of Pharmaceutical Sciences, Universiti Sains Malaysia, 11800, Gelugor, Penang, Malaysia.
Nasopharyngeal carcinoma (NPC) is a distinctive epithelial cancer closely associated with Epstein-Barr Virus (EBV) infection, posing significant challenges in diagnosis and treatment due to its resistance to conventional therapies and high recurrence rates. Current therapies, including radiotherapy and chemotherapy, exhibit limited efficacy, particularly in recurrent or metastatic cases, highlighting the urgent need for novel therapeutic strategies. Targeting EBV oncoproteins, such as Epstein-Barr Virus encoded Nuclear Antigen 1 (EBNA1), Latent Membrane Protein 1 (LMP1), and Latent Membrane Protein 2 (LMP2), presents a promising therapeutic avenue in NPC treatment.
View Article and Find Full Text PDFTrends in insecticide resistance in natural populations of Culex quinquefasciatus and its impact on mosquito fitness in Dschang, West Cameroon.
Parasitol Res
January 2025
Plant Production Department, College of Food and Agricultural Sciences, King Saud University, P.O. Box. 2460, 11451, Riyadh, Saudi Arabia.
Specific information about the dispersion of Culex quinquefasciatus from Dschang in western Cameroon is scarce, and evidence-based interventions are needed. Common use of larvicides and adulticides conduct to the development of vectors resistance which can lead to deep biological changes, including fitness costs. We assessed the profile of insecticide resistance in field populations of Cx.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!